Neurol. praxi. 2020;21(4):301-306 | DOI: 10.36290/neu.2020.084

Immunosuppressive treatment of multiple sclerosis and risk (of reactivation) of viral hepatitides

MUDr. Václav Hejda1, MUDr. Aleš Tvaroh, Ph.D.2
1 Oddělení gastroenterologie a hepatologie, Interní klinika FN Plzeň a LF UK v Plzni
2 Neurologické oddělení, Krajská zdravotní, a. s. - Nemocnice Teplice, o. z., Merck spol. s r. o.

The article presents a current perspective on the risk of reactivation of viral hepatitides in association with the administration of drugs with an immunosuppressive effect to treat multiple sclerosis. The aim of the article is to provide a practical approach for testing viral hepatitides prior to initiation of immunosuppressive treatment, taking into account recommendations resulting from the summaries of individual products.

Keywords: viral hepatitis, multiple sclerosis, immunosuppressive treatment.

Received: July 21, 2020; Accepted: July 27, 2020; Prepublished online: July 27, 2020; Published: September 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hejda V, Tvaroh A. Immunosuppressive treatment of multiple sclerosis and risk (of reactivation) of viral hepatitides. Neurol. praxi. 2020;21(4):301-306. doi: 10.36290/neu.2020.084.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bortlík M, Ďuricová D, Douda T, Konečný M, Koželuhová J, Novotný A, Zbořil V, Prokopová L., Kohout P, Stehlík J, Shonová O, Mareš K, Hrdlička L, Matějková P, Šerclová Z, Nedbalová L, Tomanová M, Liberda M, Hradský O, Mitrová K, Drastich P, Falt P, Březina J, Vaňásek T, Volfová M, Kalvach J, Pipek B, Mikoviny Kajzrlíková I, Mináriková P, Grega T, Poredská K, Kolář M, Lukáš M. Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. Gastroent Hepatol 2019; 73(1): 11-24. Go to original source...
    2. Calogero A, Sagnelli E, Creta M, Angeletti S, Peluso G, Incollingo P, Candida M, Minieri G, Carlomagno N, Dodaro CA, Ciccozzi M, Sagnelli C. Eradication of HCV infection with the Direct-Acting Antiviral Therapy in renal allograft recipients. BioMed Res Int. 2019. Go to original source...
    3. Chakravarty EF. Viral infection and reactivation in autoimmune disease. Arthritis Rheum 2008; 58(10): 2949-2957. Go to original source... Go to PubMed...
    4. Cheng AL, Hsiung CA, Su IJ. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37(6): 1320-1328. Go to original source... Go to PubMed...
    5. EPIDAT. Epidemiologická databáze Státního zdravotního ústavu Praha. Dostupné na: http://www.szu.cz/publikace/data/infekce-v-cr.
    6. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370-398. Go to original source... Go to PubMed...
    7. European Association for the Study of the Liver, EASL 2018. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69(2): 461-511. Go to original source... Go to PubMed...
    8. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58. Go to original source... Go to PubMed...
    9. Fraňková, Šperl J, Ročeň M, Adamec M, Trunečka P, Špičák J. Reaktivace hepatitidy B jako komplikace léčby lymfomu. Čes a Slov Gastroent a Hepatol 2009; 63(6): 280-283.
    10. Hui CK, Cheung WW, Zhang HY. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy [published correction appears in Gastroenterology 2006; 131(4): 1363]. Gastroenterology 2006; 131(1): 59-68. Go to original source... Go to PubMed...
    11. Husa P, Šperl J, Urbánek P, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Gastroenterol Hepatol 2017; 71(5): 419-437. Go to original source...
    12. Chmelová K, Fraňková S, Šperl J. Cytomegalovirová infekce a játra. Gastroenterol a Hepatol 2017; 71(6): 517-523. Go to original source...
    13. Kohtaro O. Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy J Clin Transl Hepatol 2016; 4(3): 206-227.
    14. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136(5): 699-712. Go to original source... Go to PubMed...
    15. Lau GK, Yiu HH, Fong DY. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125(6): 1742-1749. Go to original source... Go to PubMed...
    16. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012; 156: 743-745. Go to original source... Go to PubMed...
    17. Lok AS, McMahon BJ, Brown RS, Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 2016; 63: 284-306. Go to original source... Go to PubMed...
    18. Loomba R, Rowley A, Wesley R. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy [published correction appears in Ann Intern Med 2009; 150(9): 657-8]. Ann Intern Med 2008; 148(7): 519-528. Go to original source... Go to PubMed...
    19. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148(1): 221-244.e3. Go to original source... Go to PubMed...
    20. Stroffolini T, Sagnelli E, Gaeta GB, Sagnelli C, Andriulli A, Brancaccio G, Pirisi M, Colloredo G, Morisco F, Furlan C, Almasio PL, EPACRON study group. Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. Eur J Intern Med 2017; 38: 68-72. Go to original source... Go to PubMed...
    21. Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620. doi: 10.4254/wjh.v5.i11.612. Go to original source... Go to PubMed...
    22. Urbánek P, Husa P, Šperl J, Plíšek S, Rožnovský L, Kümpel P. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C. Gastroent Hepatol 2019; 73(2): 101-125. Go to original source...
    23. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3(6): 333-340. Go to original source... Go to PubMed...
    24. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307. Go to original source... Go to PubMed...
    25. Yeo W, Zee B, Zhong S. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311. Go to original source... Go to PubMed...
    26. Aktuální SPC uvedených léčivých přípravků LP dostupné z: http://www.sukl.cz/modules/medication/search.php.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.